ASAM-magazine-Header

Features 

feature-stories-header

Public Comment Open: Focused Update of the National Practice Guideline

by Staff | July 2, 2019

Beginning today for a period of three weeks, the American Society of Addiction Medicine (ASAM) has made available for member and public comment a draft of the focused update of the National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use.

Overview

The National Practice Guideline was developed to provide information on the evidence-based treatment of opioid use disorder and address all of the FDA-approved medications available to treat addiction involving opioid use and opioid overdose. Since its publication in 2015, new products/formulations, guidelines, and science in the field have emerged; impelling the need for a focused update.  

Methodology

ASAM contracted with the Research Triangle Institute (RTI) to lead this effort using a structured consensus process (i.e. RAND/UCLA Appropriateness Method (RAM)), which combines scientific evidence with clinical knowledge to yield a set of recommendations based on a rating panel process.

Instructions for Review

Please click here to download the draft guideline and add comments using the ‘insert comment’ feature only to the updated sections of the document (indicated in blue), with the understanding that this is a focused (not full) update. Any comments that do not fall under this scope will only be considered for the full update in the future. We kindly request that you include line numbers for reference and that the focus of your comments is around the following kinds of questions:

1.      Is the content concise, easy to understand, and relevant?

2.      Are the recommendations stated specifically and unambiguously?

3.      Are there any inaccuracies that may possibly affect patient care?

The deadline to submit comments is July 22, 2019. Upon completion, please save the document, indicate in the email your full name and the name of the organization you are representing (if any), and return to Taleen Safarian at tsafarian@asam.org.

Please also note that ASAM requires all reviewers to disclose any relevant relationships and potential conflicts of interest, and any comments submitted without completing the disclosure form will not be considered.

If you have any questions, please contact Taleen Safarian at tsafarian@asam.org or 301-547-4123. Thank you in advance for your participation in this important initiative. We look forward to your feedback.

Recent News

asam magazine

Public Comment Open: Focused Update of the National Practice Guideline

by Staff | Jul 02, 2019

Beginning today for a period of three weeks, the American Society of Addiction Medicine (ASAM) has made available for member and public comment a draft of the focused update of the National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use.

Overview

The National Practice Guideline was developed to provide information on the evidence-based treatment of opioid use disorder and address all of the FDA-approved medications available to treat addiction involving opioid use and opioid overdose. Since its publication in 2015, new products/formulations, guidelines, and science in the field have emerged; impelling the need for a focused update.  

Methodology

ASAM contracted with the Research Triangle Institute (RTI) to lead this effort using a structured consensus process (i.e. RAND/UCLA Appropriateness Method (RAM)), which combines scientific evidence with clinical knowledge to yield a set of recommendations based on a rating panel process.

Instructions for Review

Please click here to download the draft guideline and add comments using the ‘insert comment’ feature only to the updated sections of the document (indicated in blue), with the understanding that this is a focused (not full) update. Any comments that do not fall under this scope will only be considered for the full update in the future. We kindly request that you include line numbers for reference and that the focus of your comments is around the following kinds of questions:

1.      Is the content concise, easy to understand, and relevant?

2.      Are the recommendations stated specifically and unambiguously?

3.      Are there any inaccuracies that may possibly affect patient care?

The deadline to submit comments is July 22, 2019. Upon completion, please save the document, indicate in the email your full name and the name of the organization you are representing (if any), and return to Taleen Safarian at tsafarian@asam.org.

Please also note that ASAM requires all reviewers to disclose any relevant relationships and potential conflicts of interest, and any comments submitted without completing the disclosure form will not be considered.

If you have any questions, please contact Taleen Safarian at tsafarian@asam.org or 301-547-4123. Thank you in advance for your participation in this important initiative. We look forward to your feedback.

ASAM Weekly Commentary

ASAM Weekly
by

Education

web-hero-BEST

The ASAM Board Examination Study Tool (BEST) helps prepare physicians for the ABPM certification/re-certification examination utilizing an interactive and engaging format.

  • 700 Board-Style Self-Assessment Questions
  • Developed, reviewed and mapped to the ABPM exam blueprint content areas by national experts
  • Flexible learning modes allow users to design their study sessions and focus on specific topics
  • Personalized Reporting 
  • Access personal performance analysis reports and create a personalized study guide based on responses to the question bank.

Learn More>>>

MOC Guide

Considering a career in Addiction Medicine or expanding your practice services?

Physicians who have a primary ABMS board may apply to take the ABPM Addiction Medicine exam to become or continue to be an addiction medicine specialist. This specific pathway will expire in 2021. Download the NEW ASAM Information Guide on Certification and MOC.

Click here

New Resources

JAM Podcast

Journal of Addiction Medicine May/June 2019, Volume 13, Issue 3;

In episode thirteen of Addiction Medicine: Beyond the Abstract, we are joined by Dr. Jessica Gray. In her recent article, Dr. Gray discusses a case of a woman who was able to continue opioid agonist treatment during the postpartum period while she remained incarcerated, in a system that generally did not allow for opioid agonist treatment during incarceration except during pregnancy. #AddictionMedicine 

Click to listen

Drug court resources

Drug Court Resources

Tens of thousands of Americans access addiction pharmacotherapies through drug courts every year. New resources are now available. Created in partnership with the NADCP National Association of Drug Court Professionals.